Barak Uri, Rosenthal Yoav, Arami Amir, Kosashvili Yona, Velkes Steven
Department of Orthopedic Surgery, Rabin Medical Center (Beilinson Campus), Petah Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Harefuah. 2017 Jul;156(7):433-437.
The widespread use of bisphosphonates for treating osteoporosis in the last two decades has raised concern about the complication of atypical hip fractures secondary to bisphosphonate treatment. These fractures may be the result of a minor trauma to the hip or without any trauma at all. It may be heralded by prodromal groin or hip pain. Prolonged bisphosphonate treatment and atypical fractures may exist, but the nature and the extent of this linkage are still unknown. Currently, there is a lack of adequate evidence-based methods or a consensus about the treatment of this unique phenomenon.
We retrospectively examined the records of all subtrochanteric hip fracture cases admitted to our department in the years 2010-2014. During that period, we treated a total of 1315 patients:726 patients with pertrochanteric fractures, 514 patients with subcapital fractures and 75 patients with distal subtrochanteric fractures. Among those, 16 patients (1.2%) qualified as atypical hip fractures. The location of the fracture, period of bisphosphonates use, fixation type, complications and recovery were recorded.
The average age of the patients in our study was 76.9 years. All patients were treated with bisphosphonates and over 80% of the patients were treated specifically with Alendronate prior to the fracture. Mean treatment time was 7.8 years. Most of the fractures (75%) were subtrochanteric, and the others were at the femur midshaft. All patients received surgical fixation and all accomplished union of the fractures.
It seems reasonable to assume a causative relationship between a long term use of bisphosphonates and the occurrence of atypical hip fractures. It is a relatively rare complication; nevertheless, it should be kept in mind during a long term use of bisphosphonates. According to our department's clinical experience we found no delay in bone union with these atypical hip fractures. It seems reasonable to prophylactically fixate atypical stress fractures before they become a full fracture.
在过去二十年中,双膦酸盐广泛用于治疗骨质疏松症,这引发了人们对双膦酸盐治疗继发非典型髋部骨折并发症的关注。这些骨折可能是髋部受到轻微创伤的结果,或者根本没有任何创伤。前驱性腹股沟或髋部疼痛可能是其先兆。双膦酸盐的长期治疗与非典型骨折可能存在关联,但这种关联的性质和程度仍不清楚。目前,对于这种独特现象的治疗,缺乏充分的循证方法或共识。
我们回顾性检查了2010年至2014年期间我院收治的所有转子下髋部骨折病例的记录。在此期间,我们共治疗了1315例患者:726例转子间骨折患者、514例股骨头下骨折患者和75例转子下远端骨折患者。其中,16例患者(1.2%)符合非典型髋部骨折的标准。记录了骨折的位置、双膦酸盐使用时间、固定类型、并发症和恢复情况。
我们研究中的患者平均年龄为76.9岁。所有患者均接受双膦酸盐治疗,超过80%的患者在骨折前专门接受阿仑膦酸钠治疗。平均治疗时间为7.8年。大多数骨折(75%)位于转子下,其他骨折位于股骨干中部。所有患者均接受了手术固定,所有骨折均实现愈合。
长期使用双膦酸盐与非典型髋部骨折的发生之间存在因果关系,这似乎是合理的。这是一种相对罕见的并发症;然而,在长期使用双膦酸盐期间应予以关注。根据我院的临床经验,我们发现这些非典型髋部骨折的骨愈合没有延迟。在非典型应力骨折完全骨折之前进行预防性固定似乎是合理的。